breast-cancer-vascular-conference-2019-scientifictracks

2 / 8

Page 20
Volume 2 Journal of Molecular Cancer Breast Cancer & Vascular Conference 2019
February 25-26, 2019
February 25-26, 2019 London, UK
Joint event on
World Congress on Breast Cancer
Vascular Biology & Surgeons Meeting
5th International Conference on
&
Calmodulin antagonists as potential therapeutic agents for cancer treatment “Breast Cancer”
Falah AM Salih
Biotechnology Research Institute, Malaysia
Although cancer research undergone a rapid expansion, there is no potential cure and the disease remains one of the leading
causes of mortality worldwide. Breast cancer continue as the most female malignancy and a major cause of death in middle-
aged women. With that, urgent novel potentail theraputic agents are required. Calmodulin regulates many biological processes.
Calmodulin antagonists have been reported to induce apoptosis and inhibit tumour cell growth. However, the potential effects of
these target agents on various cancer within the molecular levels are poorly understood. In this presentation, we aimed to provide
a global view on the latest molecular understanding of cancer development and treatment with special emphasise on breast cancer.
In adition, successful preliminary trial was made to find a novel target for breast cancer treatment. Methods: Human breast cancer
cell lines; ER-positive; MCF-7, T47D, and ER-negative MDAMB-231 were incubated and grown with calmodulin antagonists;
Tamoxifen, W-7, W5, Trifluoperazine and Phenothiazine.The proliferative and cytotoxicity ability was analysed via WST-8 assay
on both ER-positive and ER-negative cell lines.The minimum inhibitory concentration was estimated using GraphPad Prism 7.
Moreover, Apoptosis was preliminary examine by using DNA fragmentation technique. Gene expression of BRCA1 gene in cell
lines were analysed by real-time PCR. Findings: Calmodulin antagonists effectively reduced cell growth of both ER-positive and
ER -negative human breast cancer cell lines.The minimum inhibitory concentration, IC50 values of CaM antagonists were between
the ranges of 10 to 50µM.There was reduction in calmodulin levels estimated from the samples in comparative to control cells.
Rate of gene expressions from target cells were reduced by the addition of the antagonists. DNA fragmentation analysis shows that
treatment via CaM antagonists induced apoptosis of programmed cell death in breast cancer cell lines. Conclusion and Significance:
The findings suggested that calmodulin strongly involved in tumour cell growth and regulation in breast cancer. It can be useful
therapeutic strategy for the treatment of breast cancer. This is preliminary finding, further sequencing for the exons that response
strongly to the treatment is going on.
Biography
Dr Falah achieved his PhD in 1986 from University of Delhi in Medical Biochemistry and Molecular Biology. Since he was involved in teaching in medical schools,
same time involved in research mainly on Molecular Bases of Cancer. His main field of experience in molecular Biology. Cureently he is working as Professor of
Molecular Biology in the Faculty of Medicine and Health Sciences, University Sabah Malaysia (UMS).
Falah AM Salih, J Molecular Cancer
Volume 2